Patrick Trojer

Intarcia Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index7.8kcitations161works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epigenetics and DNA Methylation(84), Cancer-related gene regulation(63), Chromatin Remodeling and Cancer(43), Histone Deacetylase Inhibitors Research(42), Protein Degradation and Inhibitors(41)

Publications161 total

BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer
Journal of Clinical Investigation·2025· 2 citedOpen Access
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Materials and Methods from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S1 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Data from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Data from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S5 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
Supplementary Table S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Danny Reinberg(11), Richard Cummings(11), Victor Gehling(9), Jean-Christophe Harmange(8), Gerald Brosch(8), Brian K. Albrecht(7), Feng Zhao(7), James E. Audia(7), Marie Classon(6), Srividya Balasubramanian(6), Ingo Bauer(6), Shilpi Arora(5), Christopher G. Nasveschuk(5), Robert M. Campbell(5), Stefan Graessle(5), Amy Gustafson(4), Kaylyn E. Williamson(4), Jennifer Busby(4), Yichin Liu(4), David Arnott(4)